ArticleJournal of neurology2025
Video head impulse test differentiates RFC1-CANVAS, FGF14-SCA27B, and idiopathic late-onset cerebellar ataxias.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quantitative Ocular Motor / Vestibular Assessment in Patients with Spinocerebellar Ataxia Type 3 (SCA3, Machado Joseph Disease) - Systematic Review of the Literature.Cerebellum (London, England) · 2026Pooled it
- An update on neuro-otology and neuro-ophthalmology - focusing on new developments in the last three years.Journal of neurology · 2026Review
- Frequency and phenotype of GAA-FGF14 disease in bilateral vestibulopathy syndromes: insights from repeat expansion carriers, including a case of co-occurrence with RFC1-related CANVAS.Journal of neurology · 2026Article
- Oculomotor abnormalities in patients with cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) reflect midline cerebellar impairment.Journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRFC1-related CANVAS and FGF14-related SCA27B are recently recognized genetic causes of late-onset cerebellar ataxia (LOCA). Despite advances in genetic testing, most panels do not detect these intronic repeat expansions, often resulting in repeated testing, delayed diagnosis, and greater patient burden. Vestibular dysfunction is common in both disorders and may help differentiate them from idiopathic LOCA (ILOCA) subtypes, guiding targeted genetic testing.
objectivesTo evaluate whether vestibulo-ocular reflex (VOR) gain measured by video head impulse test (vHIT) can differentiate CANVAS and SCA27B from ILOCA.
methodsWe reviewed 290 records of individuals with suspected cerebellar ataxia at the Johns Hopkins Ataxia Center (2023-2025). VOR gains were assessed using vHIT and compared across groups. Diagnostic thresholds were determined using receiver operating characteristic curves, with significance set at p < 0.05.
resultsFifth-nine participants were included: 10 CANVAS, 33 SCA27B, and 16 ILOCA, and matched with 31 controls. Bilateral vestibulopathy (VOR gain < 0.6) was present in 80% of CANVAS, 18% of SCA27B, and none of ILOCA (p = 0.024). Mean horizontal VOR gains were significantly lower in CANVAS (0.22) and SCA27B (0.85) than in ILOCA (1.11; p < 0.001). VOR gains < 0.70 differentiated CANVAS/SCA27B from ILOCA (100% specificity, 44% sensitivity), while a threshold of 0.50 distinguished CANVAS from SCA27B (91% specificity and 70% sensitivity). DISCUSSION: Reduced VOR gains were common in both CANVAS and SCA27B, and not observed in ILOCA. vHIT metrics may assist in distinguishing these genetic ataxias from ILOCA and each other, supporting potential utility as physiologic biomarkers and guiding targeted genetic testing.
Indexed as
Identifiers
41055766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.